Suppr超能文献

个性化组织工程动脉作为血管移植移植物:在绵羊身上的安全性研究。

Personalized tissue-engineered arteries as vascular graft transplants: A safety study in sheep.

作者信息

Jenndahl Lachmi, Österberg Klas, Bogestål Yalda, Simsa Robin, Gustafsson-Hedberg Tobias, Stenlund Patrik, Petronis Sarunas, Krona Annika, Fogelstrand Per, Strehl Raimund, Håkansson Joakim

机构信息

VERIGRAFT AB, Arvid Wallgrensbacke 20, 413 46, Göteborg, Sweden.

Sahlgrenska Academy, Institution of Medicine, Department of Molecular and Clinical Medicine, Blå Stråket 5 B Wallenberg Laboratory, 41345 Gothenburg, Sweden.

出版信息

Regen Ther. 2022 Sep 7;21:331-341. doi: 10.1016/j.reth.2022.08.005. eCollection 2022 Dec.

Abstract

Patients with cardiovascular disease often need replacement or bypass of a diseased blood vessel. With disadvantages of both autologous blood vessels and synthetic grafts, tissue engineering is emerging as a promising alternative of advanced therapy medicinal products for individualized blood vessels. By reconditioning of a decellularized blood vessel with the recipient's own peripheral blood, we have been able to prevent rejection without using immunosuppressants and prime grafts for efficient recellularization Recently, decellularized veins reconditioned with autologous peripheral blood were shown to be safe and functional in a porcine study as a potential alternative for vein grafting. In this study, personalized tissue engineered arteries (P-TEA) were developed using the same methodology and evaluated for safety in a sheep model of carotid artery transplantation. Five personalized arteries were transplanted to carotid arteries and analyzed for safety and patency as well as with histology after four months All grafts were fully patent without any occlusion or stenosis. The tissue was well cellularized with a continuous endothelial cell layer covering the luminal surface, revascularized adventitia with capillaries and no sign of rejection or infection. In summary, the results indicate that P-TEA is safe to use and has potential as clinical grafts.

摘要

心血管疾病患者常常需要替换或绕过病变血管。鉴于自体血管和合成移植物都存在缺点,组织工程作为个性化血管的先进治疗药物产品的一种有前景的替代方案正在兴起。通过用受体自身外周血对脱细胞血管进行再处理,我们能够在不使用免疫抑制剂的情况下预防排斥反应,并为高效再细胞化准备移植物。最近,在一项猪研究中,用自体外周血再处理的脱细胞静脉作为静脉移植的潜在替代物被证明是安全且有功能的。在本研究中,使用相同方法开发了个性化组织工程动脉(P-TEA),并在绵羊颈动脉移植模型中评估其安全性。将五条个性化动脉移植到颈动脉,并在四个月后分析其安全性、通畅性以及组织学情况。所有移植物均完全通畅,无任何阻塞或狭窄。组织再细胞化良好,管腔表面覆盖有连续的内皮细胞层,外膜有毛细血管再血管化,且无排斥或感染迹象。总之,结果表明P-TEA使用安全,有作为临床移植物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff43/9463533/c23b6eaef419/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验